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REVIEW
Abstract: Hypertension occurs frequently among hemodialysis (HD) patients and can be
due to many factors, such as salt intake, elevated sympathetic tone, and uremic toxins. It is
responsible for the high cardiovascular risk associated with renal disease. Generally, in HD
patients, while there is an elevation of systolic blood pressure (BP), diastolic BP seems to
decrease, and the resultant effect is high pulse pressure, which can have a deleterious effect
on the cardiovascular system. Although controversial, in the HD population the relationship
between BP and risk of death seems to be U shaped, probably because of pre-existing cardiac
disease in patients with the lowest BP. In chronic kidney disease, BP lower than 130/80 mmHg
is recommended, but an appropriate target for BP in the HD population remains to be
established. Moreover, there is no consensus regarding which routine peridialysis BP (pre- or
post-dialysis BP, or both) can ensure the diagnosis of hypertension in this population.
Ambulatory BP monitoring remains the gold standard to quantify the integrated BP load applied
to the cardiovascular system. As well, home BP assessment could contribute to improve the
definition of an optimal BP in the HD population. An ideal goal for post-dialysis systolic BP
seems to be a value higher than 110 mmHg and lower than 150 mmHg. However, HD patients
are generally old and often have cardiac complications, so a reasonable pre-dialysis target
systolic BP could be 150 mmHg. It is prudent to suggest that an improvement in BP control is
necessary in the HD population, first by slow and smooth removal of extracellular volume
(dry weight) and thereafter by the use of appropriate antihypertensive medication.
Keywords: hemodialysis, hypertension, blood pressure measurement, peridialysis blood
pressure, blood pressure control
Introduction
It is well recognized that arterial hypertension is a powerful predictor of cardiovascular
disease, including stroke, coronary heart disease, and peripheral arterial disease
(MacMahon et al 1990). Its prevalence of 20% in the general population (ESH–ESC
2003) increases with age, but in hemodialysis (HD) patients and those with end-
stage renal disease (ESRD) the prevalence is much higher, reaching 70%–80% (office
pre-dialysis blood pressure [BP]) (Charra et al 2004; Kiss et al 2004), and is associated
with a very high cardiovascular risk (Foley et al 1998). This high rate of hypertension
is already observed at earlier stages of chronic kidney disease and prior to dialysis
(Levin 2003). For the NHANES III (National Health and Nutrition Examination
Survey), the prevalence strongly increases from a glomerular filtration rate lower
than 60 mL/min (National Kidney Foundation 2002).
Moreover, uncontrolled hypertension in renal patients before ESRD has been
identified as a major risk factor for damaging kidney function and also increasing
the rate of cardiovascular complications. At the stage of dialysis, this hemodynamic
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abnormality can increase cardiovascular mortality by 3-fold
(Lucas et al 2003). A high proportion of cardiovascular
morbidity and mortality related to coronary artery disease
and left ventricular hypertrophy occurs in patients with
chronic renal disease. The increase in risk is partly
determined by classical risk factors observed in the general
population, such as increased age, hypertension, smoking,
diabetes, and hyperlipidemia (Levey and Eknoyan 1999).
Pathogenesis of hypertension in patients with renal disease
as in dialysis patients is multifactorial but may also vary
according to the underlying renal disease (Table 1)
(Campese 2000).
Besides the classical risk factors, uremic specific risks
such as anemia, hyperphosphatemia, and inflammation can
also contribute to the very high cardiovascular mortality
rates, accounting for about 50% of the death rate; this is
approximately 20–30 times the risk observed in the general
population (Kimura et al 1996; Foley et al 1998; Horl and
Horl 2002; Locatelli et al 2004). In summary, hypertension
is a common occurrence in patients with uremia, and this is
especially so in ESRD.
This review is devoted to hypertension and HD and
attempts to address three important issues regarding BP in
this population: (1) What is the target BP level associated
with the lowest cardiovascular risk in HD patients? (2) What
is the most appropriate procedure and timeline to measure
BP in the particular population of patients submitted three
times a week for dialysis treatment? (3) How can high BP
best be managed in this population?
BP level and cardiovascular risk
In the general population a linear relationship has been
demonstrated between elevation of BP and cardiovascular
mortality (MacMahon et al 1990; Prospective Studies
Collaboration 2002), but in HD patients that association
remains controversial (Schömig et al 2001). A systematic
review of the evidence does not readily reveal the so-called
linear relationship between elevated BP and cardiovascular
mortality in this population. Indeed, in HD patients,
hypotension, frequently induced by fluid removal, could
affect coronary perfusion. The associated decrease of BP
during the session could involve a cardiovascular risk. Zager
et al (1998) have observed a U-shaped relationship between
post-dialysis systolic BP and cardiac and vascular
(peripheral and cerebral) mortality in HD patients (n = 5433).
A significant increase in cardiovascular risk was noted when
systolic BP was either higher than 180 mmHg or below
110 mmHg. These cut-off points were also mentioned for
pre-dialysis systolic BP by Port et al (1999), studying HD
patients (n = 4839) from the US Renal Data System. This
differs from the classical J-shaped curve relating BP levels
to cardiovascular mortality in patients with essential
hypertension (Cruickshank 1988). However, the association
between low BP and increasing mortality could be attributed
either to the poor overall health status of patients (Zager et
al 1998) or to cardiac failure as a consequence of the
presence of long-term hypertension (D’Amico and Locatelli
2002).
Evidence presented in a study by Mazzuchi et al (2000)
seems to suggest that a distinction could be made between
the early and late mortality among HD patients (n = 405)
who survived at least 2 years. Thus a U-shaped curve in HD
patients during the first year of treatment (early mortality)
was confirmed, while in the longer term (ie, from the fifth
year) the relationship between mortality and BP control
appeared to show an increased risk only for the higher BP
values (eg, systolic/diastolic BP > 160/90 mmHg). This has
led to the suggestion that the association between
hypotension and mortality in HD patients may be related
not to cardiovascular causes but to other medical conditions
(Mazzuchi et al 2000).
It is clear that specific optimal systolic and diastolic BP
targets for HD patients are needed; however, the BP
guidelines as set by the JNC 7 (Joint National Committee
7th Report) and European Society of Hypertension–
European Society of Cardiology (ESH–ESC) (Chobanian
et al 2003; ESH–ESC 2003) are probably not applicable for
such patients (London 2001). Moreover, establishing a
precise definition of the lowest acceptable limit of BP,
especially for pre-dialysis systolic BP (in older patients),
would be of great clinical interest. In summary, although
controversial, the relationship between BP and
cardiovascular risk in the HD population appears to be
characterized by a U-shaped curve, probably due to the
presence of pre-existing cardiac disease or other severe
medical conditions in patients with the lowest BP levels.
Table 1 Pathophysiological factors playing a role in high blood
pressure in end-stage renal disease
Sodium sensitivity
Sympathetic and renin–angiotensin system activation
Decrease in nitric oxide availability
Increase in endothelin concentration
Arteriovenous fistula
HyperparathyroidismVascular Health and Risk Management 2005:1(3) 237
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Which target BP should be used
in HD?
The latest JNC 7 and ESH–ESC guidelines defined the
optimal BP by systolic and diastolic levels lower than
120/80 mmHg and hypertension as levels of 140/90 mmHg
or higher. Thus, in patients with hypertension the goal of
treatment is to reduce BP to below 140/90 mmHg and even
lower in patients with diabetes or renal disease (Chobanian
2003; ESH–ESC 2003). In these groups, a target lower than
130/80 mmHg has been proposed, which is in total
agreement with the target BP set by the National Kidney
Foundation (2004) guidelines. However, these guidelines
are unfortunately not applicable to the HD population.
Moreover, it is a fact that BP is not well controlled in
hypertensive HD patients. For instance, in these patients,
Agarwal et al (2003) reported a rate of 70% of uncontrolled
BP (pre-dialysis systolic BP > 150 or diastolic BP
> 85mmHg). Furthermore, among this uncontrolled
population 12% were untreated and 58% were inadequately
treated (Agarwal et al 2003).
The question is clearly: what is the ideal in BP
management in HD patients? Surprisingly, there is no
consensus as to normal BP limits in HD patients. Simply
put, the basis for the lack of insight appears to be the
difficultly in identifying the best BP measurement time in
patients with HD, and the reason for the lack of this
information is hemodynamic instability of these patients.
To summarize, in chronic kidney disease, BP lower than
130/80 mmHg is recommended, but the optimal BP target
in such patients is yet be fully established.
HD and high BP
Normally, patients undergo HD treatment three times a
week; this results in alteration in extracellular fluid volume,
and it is during these sessions that many patients experience
large fluctuations in BP. In HD patients, the basis for the
occurrence of high pre-dialysis BP can result from a number
of factors: changes in extracellular volume (ie, expansion);
low compliance due to restricted salt intake (Khosla and
Johnson 2004); sympathetic and renin–angiotensin over-
activation (Blankestijn 2004); retention of uremic toxins,
which can cause vasoconstriction; accumulation of
asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of nitric oxide synthase (Zoccali et al 2003); and
other factors such as parathyroid hormone secretion,
erythropoietin treatment, endothelial dysfunction, and
obesity associated insulin resistance (Mailloux and Levey
1998; Campese 2000).
It has also been noted that shortening of the dialysis
session results in difficulty reaching the optimal dry weight
(Flanigan 2000; Pérez-Garcia et al 2001). This is believed
to be related to insufficient removal of volume during the
HD session, which seems to occur in spite of increasing
sodium concentration in the dialysis bath. The resultant
effect appears to be the maintenance of high extracellular
volume and pre-dialysis BP (Charra et al 2004; Khosla and
Johnson 2004). Achieving a lower dry weight, based on
clinician best judgment, and lengthening of HD session time
have proved beneficial in the management of hypertension
without the use of antihypertensive medications. However,
the decrease in BP by such an approach is not immediate,
and it could take weeks or months before a stable reduction
in BP is observed; thus, this has been labeled “the lag
phenomenon” (Chazot et al 1999). It has been recently
proposed that other types of dialysis procedure, such as slow
but long duration dialysis (3 times 8 hours per week), short
daily dialysis (2–3 hours daily, 6 times per week), or even
nocturnal dialysis (6–7 overnight sessions per week), can
improve the management of hypertension in HD patients
(Kiss et al 2004). Reduction of dietary salt intake, fluid
restriction, and decreasing sodium concentration in the
dialysis bath have also proved effective and viable methods
of lowering BP in HD patients (Kooman et al 2004).
It seems that during the dialysis session the removal of
fluids results in a progressive decline in stroke volume and
cardiac output and a concomitant increase in systemic
vascular resistance (Daugirdas 2001). These modifications
are associated with a reduction of vascular compliance in
response to dialysis which may also contribute to the
increased cardiovascular risk (Gadegbeku et al 2003).
However, one method of dialysis that may be beneficial in
decreasing BP in patients is the use of biocompatible dialysis
membranes. It has been reported that the use of this
technique over a course of 6 weeks decreased the mean 24-
hour BP in diabetic patients (Schröder et al 2001). It was
further postulated that one contributing factor for the
antihypertensive effect in these patients was the removal of
ADMA and changes in ADMA/arginine ratio resulting in
“upregulation” of the nitric oxide/arginine pathway.
It is recognized that the relationship between BP and
fluid removal during dialysis is influenced by the cardiac
status of the patient. For example, lowering of an equal
intradialytic plasma volume caused a more substantialVascular Health and Risk Management 2005:1(3) 238
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decrease of BP in patients with cardiac failure when
compared with those free of heart failure (Van der Sande et
al 1998). However, it must be also stated that the relationship
between lowering of intradialytic plasma volume and
changes in BP is a controversial topic. For instance, in a
subset of patients from the HEMO Study, pre- and post-
dialysis BP were differently influenced by acute decrease
in weight (an indicator of interdialytic fluid gain) and plasma
volume (an indicator of post-dialysis volume status)
(Leypoldt et al 2002). In this study, the pre- and post-dialysis
BP were associated with larger intradialytic decreases in
bodyweight but smaller intradialytic reductions in plasma
volume. Each kilogram reduction in bodyweight during HD
was associated with 2.95 and 1.65 mmHg higher pre-dialysis
and post-dialysis systolic BP, respectively. In contrast, each
5% greater contraction of plasma volume during HD was
associated with 1.5 and 2.56 mmHg lower pre-dialysis and
post-dialysis systolic BP. It seems that weight and plasma
volume reductions were weak determinants of the
peridialysis BP. This suggests that other factors most likely
contribute to the control of BP in HD patients, such as
effective dry weight and cardiac status (Leypoldt et al 2002).
Another problem in the HD population is sleep apnea,
which independently increases the prevalence of systemic
hypertension as well as cardiac and vascular (cerebral and
peripheral) diseases (Zoccali et al 2001). This problem seems
to occur in 2%–4% of the general population (Sharabi et al
2004) but is more commonly observed in obese individuals
and diabetic patients, while in ESRD patients the prevalence
exceeds 50% (Zoccali et al 2001). It appears that
pathophysiology of sleep apnea could be more linked to
uremia itself rather than to the dialysis treatment or the mode
of dialysis (Hanly 2004).
In summary, hypertension in HD is influenced by many
factors associated with uremia but also by the amount of
hydrosaline removal during the session, as well as
cardiovascular system adaptability.
Assessment of BP profile in HD
patients
HD patients are more characterized by isolated systolic
hypertension than by elevations in both systolic and diastolic
BP, which seem to occur in fewer than 20% of that
population (Mailloux and Haley 1998). Numerous
observational epidemiological studies and randomized,
controlled trials have demonstrated that elevated systolic
BP is an independent and powerful predictor of the high
incidence of cardiovascular and renal diseases (He and
Whelton 1999).
Systolic hypertension is mainly due to a decrease in
arterial compliance and is a characteristic of aging in the
non-uremic population (Farsang and Sleight 2001; Franklin
2005). ESRD patients seem thus to have an accelerated
vascular aging process, especially in the large arteries
(London et al 1990; Agarwal 2003). When assessed by the
pulse wave velocity measurement, increased aortic stiffness
has been considered as a strong determinant of all-cause
and cardiovascular mortality in ESRD patients (Blacher et
al 1999). At any mean arterial pressure level, most HD
patients have higher systolic BP and lower diastolic BP than
control subjects with normal renal function (Agarwal 2003).
Thus, the majority of HD patients exhibit high pulse
pressure, which has also been prospectively identified as a
predictor of cardiovascular and total mortality (Amar et al
2000; Safar et al 2002). Klassen and colleagues (2002) have
suggested that even an elevation of 10 mmHg in pulse
pressure is associated with a 12% increase in risk of death.
A similar view has been expressed by Zoccali (2003), who
revealed that patients with high pulse pressure (> 70 mmHg)
had a risk of cardiovascular events more than twice that of
patients with lower pulse pressure. Therefore, it seems that
pulse pressure plays a more important role in cardiovascular
risk in uremic patients than in the general population (Pastor-
Barriuso et al 2003). However, in essential hypertension with
preserved normal renal function, cardiovascular mortality
after adjustment for confounding variables also increased
with higher aortic pulse wave velocity as noted in the uremic
population (Anderson et al 1991). The increasing evidence
that raised pulse pressure and arterial stiffening are
independent predictors of cardiovascular mortality in
hypertensive and ESRD patients has brought new challenges
in pharmacotherapy of this population of patients (Van
Bortel et al 2001).
It must be recognized that controlling BP in HD is not
an easy task, given that the extracellular volume
modifications during and between the dialysis sessions can
have a considerable and unpredictable effect on BP. So it
would be of great interest to know which BP will be more
representative of the true BP status applied to the
cardiovascular system. On the basis of this background,
Santos et al (2003) randomly studied the BP pattern of HD
patients (n = 71). This observation revealed that systolic and
diastolic BP, as well as pulse pressure, increased during the
interdialytic period (44-hour ambulatory BP monitoring;
ABPM), but this was not related to the weight gainVascular Health and Risk Management 2005:1(3) 239
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(hydrosaline accumulation) noticed during that period.
Although hypertension (defined by average 44-hour BP
≥ 135/85 mmHg) was diagnosed in 55% of the patients while
on antihypertensive medications, the Kt/V, hematocrit, or
the weekly erythropoietin dose could not explain why BP
remained uncontrolled. High rates of non-dipping (night BP
fall < 10% or night/day ratio > 0.90) were observed in 77%
on day 1 and in 83% on day 2, illustrating the lack of normal
nocturnal BP fall pattern in the majority of HD patients
(Santos et al 2003).
To summarize, in HD patients, the systolic component
of BP is increased while the diastolic seems to be decreased,
resulting in high pulse pressure which appears to have a
negative influence on the arterial tree. This characteristic,
at the functional level, occurs as a result of the accelerated
aging process. To this end, control of BP is also made
difficult by the cyclical variations of volume status.
Peridialysis BP (pre- or post-
dialysis): which predicts the best
interdialytic level?
BP seems to be acutely influenced by the dialysis session,
speed of volume removal, and counter-regulation response.
It is pertinent to examine whether one should consider the
pre-dialysis or post-dialysis BP, or both, as reliable
predictors of interdialytic BP.
Several studies assessed the prediction that can be
attributed to BP levels measured before or after the dialysis
session (Foley et al 2002; Mendes et al 2003). Post-dialysis
rather than pre-dialysis BP was found to be independently
related to increased mortality. This evidence confirmed the
superiority of post-dialysis BP to predict mortality, although
this relationship was found to be weak by others. In contrast,
it has been proposed that the average of pre- and post-dialysis
BP is a better representation of pre-dialysis BP (Mendes et
al 2003). According to Mitra et al (1999), who compared
conventional BP measurement, self-measured BP
(Dinamap), and interdialytic BP (ABPM), the 20-minute
post-dialysis BP reading was the best representative BP
parameter of the average ambulatory interdialytic BP. It
seems that pre-dialysis BP is indeed too much influenced
by a white-coat phenomenon (Mitra et al 1999).
It appears that errors in BP measurements (accuracy of
the devices, observer bias, patient behavior) coupled with
the variability of BP patterns among individuals during
dialysis could considerably limit the use of peridialysis BP
(Sankaranarayanan et al 2004). However, that opinion is
not shared by everyone. For instance, according to Zoccali
(2003), pre-dialysis BP was a better predictor of left
ventricular mass index than post-dialysis BP.
ABPM has been generally considered as the most
accurate method for evaluating BP load in the general
population as well as in HD patients (Peixoto et al 2000).
Moreover, it is a useful tool for effective management of
antihypertensive therapy. One main advantage of using
ABPM to monitor BP is the identification of altered
nycthemeral BP rhythm, which seems prevalent in HD
patients. Indeed, such diagnosis has been performed in some
mild renal disease patients with near-normal renal function
(Valero et al 1999). A blunted rhythm is common among
HD patients (eg, in 55%–75%) (Covic and Goldsmith 1999;
Chughtai and Peixoto 2003). Evidently, a complete reversal
of diurnal rhythm has been observed in fewer than 10%
(Redon 1998). One explanation that has been offered to
account for this reversal is over-activation of the sympathetic
nervous system during sleep in response to hypoxemia, an
occurrence that has been observed in the non-renal disease,
non-dipper population (Arita et al 1996). Other significant
factors that have been suggested to affect BP pattern are
decreased arterial distensibility and erythropoietin therapy
in treated hypertensive HD patients (Amar et al 1997).
Moreover, as already mentioned, a high proportion of HD
patients seem to experience sleep apnea, an abnormality
responsible for elevated nocturnal BP as described in obese
individuals and patients with essential hypertension
(Barenbrock et al 1996).
While there is solid evidence to indicate that ABPM
monitoring of BP is more reproducible than isolated
measurement of BP at pre- or post-dialysis (Peixoto et al
2000), it has also been shown that the reproducibility of
ABPM recordings poorly documents nocturnal decreases
in BP (Peixoto et al 2000). However, the non-dipping
phenomenon (Verdecchia et al 1994) in stable HD patients
has been prospectively related to a deterioration of left
ventricular function as compared with that in patients who
had a satisfactory nocturnal fall in BP (Covic et al 1997).
Non-dipping has been frequently associated to left
ventricular hypertrophy (LVH) in essential hypertension but
it is also observed in the absence of hypertension (Redon et
al 1999).
In a follow-up study of HD patients (n = 80), it was
shown that non-dippers had an impaired circadian rhythm
of autonomic function and a 9 times higher incidence than
dippers of death due to cardiovascular failure (Liu et al
2003). However, when results were adjusted for age, sex,Vascular Health and Risk Management 2005:1(3) 240
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and history of cardiovascular disease, it was suggested that
night-time systolic BP more than dipper status was
associated with cardiovascular prognosis (Amar et al 2000).
Clearly, more clinical studies are needed in this area before
this issue can be fully resolved. It is also clear that most
observations have focused on the real importance of the BP
curve analysis during the interdialytic period and not only
on the pre- or post-dialysis BP levels in assessment of the
relationship between BP and cardiovascular risk (Zoccali
2003). However, Zoccali (2003) observed that when left
ventricular mass is considered as a surrogate end point, pre-
dialysis systolic BP seems superior to post-dialysis BP and
equally informative as 24-hour ABPM when the effects of
“integrated” pressure load on the heart have to be assessed.
In summary, it is difficult to define hypertension in
dialysis because of the variation of total bodyweight during
repetitive dialysis sessions. There is no consensus regarding
which peridialysis BP can best ensure the diagnosis of
hypertension. ABPM adds important information on
nocturnal BP pattern, but more studies are needed to
integrate that technology into the assessment of
cardiovascular risk in HD patients.
ABPM and hypertension criteria
As already mentioned, defining the true BP status of HD
patients is quite difficult owing to a lack of agreement
between BP measurements made just before and after a
dialysis session. Indeed, it seems that routine BP
measurement results in an overestimation of the real BP
(Rahman et al 2002). In contrast, ABPM during the
interdialytic period has proved to be superior to the classical
sphygmomanometer method to assess the high prevalence
(about 70%) of uncontrolled hypertension among HD
patients, even those being treated with antihypertensive
medication (Covic and Goldsmith 2002; Agarwal et al 2003;
Covic et al 2003). A criterion for the classification of
hypertension in chronic HD patients has been proposed on
the basis of comparisons between 44-hour ABPM
interdialytic BP and conventional measurements, namely
systolic/diastolic BP of > 150/85 and > 130/75 mmHg, for
pre-dialysis and post-dialysis, respectively. This criterion
seems to offer a very sensitive assessment of overall BP in
these patients. However, pre- and post-dialysis BP
measurements cannot be relied upon to predict an absolute
level of mean ambulatory BP with confidence (Agarwal and
Lewis 2001; Agarwal et al 2003). Needless to say, a more
accurate assessment of target BP would be determined by
prospectively linking BP measured by ABPM to cardiac
function.
Agarwal (2002) has critically assessed measurement of
BP in HD patients. He suggested that a comparison and
subsequent analysis for agreement between two methods
of BP measurement; ie, ABPM and conventional BP
measurement analysis should be performed in the HD unit.
Indeed, there is evidence to indicate that determination of
BP in the HD unit is not a reliable predictor of the
interdialytic level and/or cardiac complications in these
patients (Agarwal 2002). The best correlation with left
ventricular mass index seems to come from ABPM,
especially the systolic BP load component, which appears
to be an independent predictor of LVH. On the other hand,
night-time ABPM was the best predictor of left ventricular
posterior wall thickness (Ertürk et al 1996). When
comparing ABPM with 2-week averaged peridialysis unit
BP measurements in 70 patients, no close relationship
between the two methods was found (Agarwal and Lewis
2001). Indeed, pre-dialysis systolic BP measurement using
conventional methods can overestimate or underestimate by
50 mmHg and 20 mmHg, respectively, when compared with
ABPM (Agarwal and Lewis 2001). Thus it seems that BP
measurement in the HD unit can be considered only as a
qualitative but not quantitative indicator of the control (or
lack of control) of BP and that an accurate measurement
can be guaranteed only by ABPM. However, this view is
not universally accepted (Nystrom et al 2002).
To summarize, ABPM remains the best technique to
calculate the integrated BP load applied to the cardiovascular
system. However, an active debate persists on the subject
of whether peridialytic BP measurement provides consistent
information in these HD patients.
Home BP
The use of automatic devices to measure BP at home has
become quite common. This approach appears to be
beneficial and more effective than office BP measurements.
In addition, the monitoring of BP at home is a cost-effective
means that could help diagnosis of undiagnosed
hypertension in dialysis patients (Agarwal 1999).
However, there are likely to be substantial errors
associated with the measurement of BP at home, although
this may be less than with office measurements. In addition,
this approach is interesting because it involves participation
of patients in the management of their own BP
measurements. There is evidence, at least in the non-renalVascular Health and Risk Management 2005:1(3) 241
Optimal BP in hemodialysis
disease hypertensive population, to indicate that this is both
helpful and beneficial to patients in terms of compliance
with medication (Yarows et al 2000). It may also provide
better information for predicting cardiovascular risk (Bobrie
et al 2004). Nevertheless, the evidence that such an approach
is beneficial in the management of BP as well as
cardiovascular risk assessment in HD patients is yet to be
validated. In summary, controlled studies need to be
designed and carried out to determine whether monitoring
of BP at home in HD patients is of benefit.
Which BP thresholds to use for
definition and control of
hypertension in the HD population
To our knowledge there is no consensus on a definition of
normal pre-dialysis BP. According to Ritz (2000) and
Locatelli et al (2004), a target pre-dialysis BP below
140/90 mmHg should perhaps be considered as normal in
the HD population. This definition should be modified
according to age (< 60 or ≥ 60 years) as proposed by the
British Renal Association (The Renal Association 1995).
As the cardiovascular risk associated with systolic BP is
minimized between 100 and 150 mmHg for pre- and post-
dialysis (Zoccali et al 2002), it has been proposed that a
reasonable treatment goal would be to stabilize the pressure
at a maximum of 150 mmHg, while an attempt should be
made to achieve a lower level in patients with normal pulse
pressure (Zoccali 2003).
However, as previously mentioned, control of
hypertension in HD patients is a challenge, despite the use
of many effective antihypertensive drugs, especially in
patients on short HD treatment time. Agarwal et al (2003),
using a less restrictive systolic BP limit (ie, target BP
< 150/85 mmHg), reported that in fewer than 30% of
hypertensive HD patients BP is adequately controlled (this
seems also to apply to the general population). Improving
control of hypertension often needs more hydrosaline
removal and knowledge of the patient’s clinical
characteristics (anephric, LVH, malignant hypertension of
long duration), which could provide information on the
different mechanisms or severity of hypertension.
Prolongation of the dialysis time could thus be beneficial
but, unfortunately, this is unpopular among HD patients.
Moreover, inconsistent use of antihypertensive therapy (ie,
only on days without dialysis to avoid hypotension during
dialysis sessions) and the use of submaximal drug dosage
are significant barriers in the control of BP.
In summary, to prevent cardiovascular mortality, an ideal
goal of systolic BP during HD appears to be at levels above
100 and below 150 mmHg when other cardiovascular risk
factors and cardiac function are controlled. Since HD
patients are generally older and cardiac complications are
frequent, a more reasonable target could be 150 mmHg;
however, lower targets should be attempted in patients with
normal pulse pressure.
Management of hypertensive
patients treated by HD
In the management of hypertension the goal is, at least, to
reach pre-dialysis BP ≤ 150/85 mmHg without any excessive
BP decrease during and just after the dialysis session (BP
must remain ≥ 110/70 mmHg) in order to avoid coronary
ischemia (Figure 1).
First, a smooth reduction in post-dialysis weight must
be reached over the course of a few weeks. In parallel,
sodium load during dialysis treatment should be limited as
required.
If necessary, prolongation of the dialysis treatment time
and/or an extra dialysis session must be implemented. It
should be recognized that the BP lowering effect is
significantly observed only after a few weeks, owing to the
lag phenomenon, and this requires patience from both
physician and patient.
Second, if target BP is not achieved after a few weeks,
antihypertensive drugs can be introduced. The choice of
antihypertensive medication needs to be tailored in
accordance with underlying pathology in the patient.
β-Blockers are an excellent choice in case of angina pectoris,
Pre-dialysis 140 and/or 90mmHg
<60y
160/90mmHg 
60y
By office and/or home BP measurement 
Non-pharmacological measures 
(low Na diet, reduction of water intake, and post-dialysis dry weight) 
Pre-dialysis BP >150/85mmHg   4–8 weeks 
Introduce antihypertensive drug (individual choice) 
Target 
Pre-dialysis BP <150 /85mmHg 
Post-dialysis BP >110/70mmHg
Diagnosis of hypertension 
Figure 1 Proposal for management of high blood pressure in hemodialysis.Vascular Health and Risk Management 2005:1(3) 242
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after myocardial infarction, and in tachyarrhythmia.
Angiotensin-converting enzyme inhibitors could be
proposed in the presence of congestive heart failure and after
myocardial infarction or in diabetic patients. Calcium
channel blockers, which have been widely prescribed in HD
patients, are useful when there is angina pectoris or systolic
hypertension or in older patients. However, there is no
evidence from randomized trials to demonstrate superiority
of one class over the others in dialysis patients (Griffith et
al 2003). There is a need for such trials to be conducted.
Recent evidence based on a retrospective study showed that
the use of calcium channel blockers could be associated
with a lower risk of mortality among ESRD patients
(Kestenbaum et al 2002). The evidence provided from the
VALUE clinical trial seems to suggest that in patients with
a high cardiovascular risk, such as the HD population,
amlodipine provided greater protection in patients with
chronic kidney disease when compared with patients
receiving valsartan. Amlodipine was even superior in
preventing myocardial infarction when compared with
valsartan (Julius et al 2004). This could be due to more
rigorous control of BP in patients treated with calcium
channel blockers. In summary, an improvement in the
control of BP is necessary in the HD population, first by a
slow and smooth removal of extracellular volume (dry
weight) and thereafter by use of antihypertensive medication
on a case-by-case basis.
Guidelines to improve BP control
in HD
The HD population is highly exposed to cardiovascular
disease. The risk is strongly influenced by hypertension,
which is present in the majority of patients. Currently,
despite the various means available to decrease BP, control
of hypertension in HD patients remains unsatisfactory (as
in the general population).
To improve the management of high BP, we agree with
Agarwal’s proposals (2003), which are as follows:
1. Make an accurate diagnosis of hypertension (repetitive
office BP measurements, self-home BP determination,
or, even better, by using ABPM).
2. Institute non-pharmacological measures, ie, salt and
water restrictions, physical exercise, decrease in dry
weight, and use of an optimal composition of the
dialysate, which respects the sodium balance (to remove,
by HD, the exact amount of sodium that has accumulated
during the interdialytic period).
3. Prescribe, as a last resort, antihypertensive agents, the
choice dictated by the characteristics of the patient (see
above).
4. In some patients, modification of the dialysis time and
frequency should be implemented with the goal of
reaching a target pre-dialysis BP below 150/85 mmHg
and a post-dialysis BP above 110/70 mmHg.
All these suggestions rely on good medical practice. There
seems to be an urgent need for prospective, randomized
studies to determine the best BP measurement technique
related to cardiovascular disease development, and the most
appropriate choice for antihypertensive management by
using the lowest dry weight, antihypertensive drugs, or both.
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